Kimberly Danae Cauley Narain1,2, Danielle Doppee3, Ning Li3, Gerardo Moreno4, Douglas S Bell3,5, Amanda L Do5, Robert W Follett5, Carol M Mangione3,6. 1. Department of Medicine, Division of General Internal Medicine and Health Services Research (GIM/HSR), University of California, Los Angeles, Los Angeles, CA, 90024, USA. KNarain@mednet.ucla.edu. 2. Center for Health Advancement, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA. KNarain@mednet.ucla.edu. 3. Department of Medicine, Division of General Internal Medicine and Health Services Research (GIM/HSR), University of California, Los Angeles, Los Angeles, CA, 90024, USA. 4. Department of Family Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. 5. Clinical and Translational Science Institute, University of California, Los Angeles, Los Angeles, CA, USA. 6. Health Policy and Management, Fielding School of Public Health, UCLA, Los Angeles, CA, USA.
Abstract
BACKGROUND: Black individuals with type 2 diabetes suffer disproportionate morbidity and mortality relative to whites with type 2 diabetes, irrespective of health insurance coverage. OBJECTIVE: Examine the impact of a primary care-embedded clinical pharmacist-led intervention (UCMyRx) on cardiovascular risk factor control among blacks with type 2 diabetes in a large healthcare system. DESIGN: We used data extracted from the electronic health records (EHR) system and a difference-in-differences study design with a propensity-matched comparison group to evaluate the impact of UCMyRx on HbA1c and systolic blood pressure (SBP) among black patients with type 2 diabetes, relative to usual care. PARTICIPANTS: Individuals with type 2 diabetes identified as either black or African American in the EHR that were ≥ 18 years of age that had the following observations during the study window (03/02/2013-12/31/18: (1) HbA1C ≥ 8%, at least once, anywhere between 365 days before and 14 days after the UCMyRx visit and a follow-up HbA1c measure within 120 to 365 days after the visit and/or (2) SBP ≥ 140 mmHg at least once between 365 days before and 14 days after the UCMyRx visit that had a follow-up SBP measure within 120 to 450 days after the visit. INTERVENTION: UCMyRx pharmacists review labs and vital signs, perform medication reconciliation, use a standardized survey to assess barriers to medication adherence, and develop tailored interventions to improve medication adherence. MAIN MEASURES: Change in HbA1c and change in SBP from before to after the first UCMyRx visit. KEY RESULTS: Having at least one visit with a UCMyRx clinical pharmacist was associated with a significant reduction in HbA1c (- 0.4%, p value = .01); however, there was no significant impact on SBP (- .051 mmHg, p value = 0.74). CONCLUSIONS: The UCMyRx intervention is a useful strategy for improving HbA1c control among blacks with type 2 diabetes.
BACKGROUND: Black individuals with type 2 diabetes suffer disproportionate morbidity and mortality relative to whites with type 2 diabetes, irrespective of health insurance coverage. OBJECTIVE: Examine the impact of a primary care-embedded clinical pharmacist-led intervention (UCMyRx) on cardiovascular risk factor control among blacks with type 2 diabetes in a large healthcare system. DESIGN: We used data extracted from the electronic health records (EHR) system and a difference-in-differences study design with a propensity-matched comparison group to evaluate the impact of UCMyRx on HbA1c and systolic blood pressure (SBP) among black patients with type 2 diabetes, relative to usual care. PARTICIPANTS: Individuals with type 2 diabetes identified as either black or African American in the EHR that were ≥ 18 years of age that had the following observations during the study window (03/02/2013-12/31/18: (1) HbA1C ≥ 8%, at least once, anywhere between 365 days before and 14 days after the UCMyRx visit and a follow-up HbA1c measure within 120 to 365 days after the visit and/or (2) SBP ≥ 140 mmHg at least once between 365 days before and 14 days after the UCMyRx visit that had a follow-up SBP measure within 120 to 450 days after the visit. INTERVENTION: UCMyRx pharmacists review labs and vital signs, perform medication reconciliation, use a standardized survey to assess barriers to medication adherence, and develop tailored interventions to improve medication adherence. MAIN MEASURES: Change in HbA1c and change in SBP from before to after the first UCMyRx visit. KEY RESULTS: Having at least one visit with a UCMyRx clinical pharmacist was associated with a significant reduction in HbA1c (- 0.4%, p value = .01); however, there was no significant impact on SBP (- .051 mmHg, p value = 0.74). CONCLUSIONS: The UCMyRx intervention is a useful strategy for improving HbA1c control among blacks with type 2 diabetes.
Authors: Juan R Canedo; Stephania T Miller; David Schlundt; Mary K Fadden; Maureen Sanderson Journal: J Racial Ethn Health Disparities Date: 2017-01-11
Authors: Ronald T Ackermann; O Kenrik Duru; Jeanine B Albu; Julie A Schmittdiel; Stephen B Soumerai; James F Wharam; Mohammed K Ali; Carol M Mangione; Edward W Gregg Journal: Am J Prev Med Date: 2015-06 Impact factor: 5.043
Authors: Elizabeth A Stuart; Haiden A Huskamp; Kenneth Duckworth; Jeffrey Simmons; Zirui Song; Michael Chernew; Colleen L Barry Journal: Health Serv Outcomes Res Methodol Date: 2014-12-01
Authors: Andrew J Palmer; Stéphane Roze; William J Valentine; Michael E Minshall; Volker Foos; Francesco M Lurati; Morten Lammert; Giatgen A Spinas Journal: Curr Med Res Opin Date: 2004-08 Impact factor: 2.580
Authors: Ariel T Holland; Beinan Zhao; Eric C Wong; Sarah E Choi; Nathan D Wong; Latha P Palaniappan Journal: J Diabetes Complications Date: 2012-10-11 Impact factor: 2.852